cobas® MPX

Improve blood and plasma safety: one test, three results



***cobas*® MPX detects and discriminates the most critical viral targets in one easy-to-use assay.**

Potential transmission of viral infections, particularly HIV-1, HIV-2, HCV and HBV is a major concern in the transfusion of blood and blood components. Transmission of these agents primarily occurs by exposure to contaminated blood or blood and plasma products, exposure to certain body tissues or fluids, by sexual contact or by an infected mother to her newborn child.

cobas® MPX is a qualitative *in vitro* nucleic acid test for the detection of HIV, HCV and HBV in serum and plasma specimens from human donors.

Your benefits

Improve blood and plasma supply safety with cobas® MPX

Provides heightened protection from transfusion-transmitted HIV-1, HIV-2, HCV, and HBV infection for recipients of donated blood or blood products

Highly sensitive and specific test with dual target approach for HIV-1 Group M and dual probes for HCV

Increased safety with detection of occult and low viremic HBV infection

Generate trusted, reproducible results with proven performance

Full-process internal control helps ensure result integrity

Stabilised real-time PCR reagents do not require calibration

True external positive controls that have no direct effect on calibration with **cobas**® MPX control kit

Leverage absolute automation to drive increased efficiency with minimal human interactions

Real-time detection and discrimination of HIV, HCV and HBV

Ready-to-use reagents do not require thawing, mixing or pouring

Flexibility to run simultaneously with other assays on the **cobas**® 5800/6800/8800 Systems

cobas® MPX performance

Limit of detection

EDTA Plasma	Units	95% LoD*	LCL/UCL
HIV-1 Group M IU/mL	IU/mL	25.7	21.1 -32.8
HIV-1 Group O	copies/mL	8.2	7.0-10.0
HIV-2	IU/mL	4.0	3.3-5.2
HCV	IU/mL	7.0	5.9-8.6
HBV	IU/mL	1.4	1.2-1.7



Key parameters

Parameter	Description
Assay targets	HIV-1 Group M, HIV-1 Group O, HIV-2, HCV and HBV
Sample type	serum, plasma, living and cadaveric donor
Pool sizes	IDT; pools of 1, 6, 24, 96 with **cobas® Synergy** software
Minimum amount of sample required	1000 µL (living donor) 300 µL (cadaveric donor)
Sample processing volume	850 µL (living donor) 150 µL (cadaveric donor)
Testing time	Approximately 3 hours

	cobas® 5800	**cobas®** 6800/8800
Open kit stability	90 days	30 days
Number of runs	40 runs (480T)	10 runs (96T) 20 runs (480T)

Comprehensive NAT menu for blood and plasma screening[2]

Blood and plasma screening tests

cobas® MPX
cobas® WNV[1]
cobas® DPX[1, 3]
cobas® HEV[1, 4]
cobas® Zika[1]
cobas® CHIKV/DENV[1, 4]
cobas® Babesia[1]

Disclaimers

*[1]For use on **cobas®** 6800/8800 systems only*

[2]Not all tests/assays available in all markets

[3]cobas DPX is an in-process test for plasma intended for further manufacture

[4]Not available in the US

Ordering information

Material number	Product name	Tests per unit (cassette)
Current Material Numbers for cobas® 6800/8800		
06997708190	**cobas®** MPX-96, CE-IVD	96 tests
06998909190	**cobas®** MPX-96, US-IVD	96 tests
06998917190	**cobas®** MPX-480, US-IVD	480 tests
06997724190	**cobas®** MPX control kit, CE-IVD	4 runs
06999069190	**cobas®** MPX control kit, US-IVD	4 runs
07002220190	**cobas®** NHP negative control kit	16 runs
New Material Numbers for cobas® 5800/6800/8800		
09040862190	**cobas®** MPX-480, CE-IVD	480 tests
09040846190	**cobas®** MPX control kit, CE-IVD	4 runs
09051554190	**cobas®** NHP negative control kit	16 runs

Published by:
Roche Molecular Systems
4300 Hacienda Drive
Pleasanton, CA 94588 USA

diagnostics.roche.com

MC-00310

Signature Page for MC--00310 v3.0

Medical Approval	Jean Stanley Medical 09-Dec-2021 23:09:24 GMT+0000

Other Approval	Kate Suileabhain Business 09-Dec-2021 23:17:09 GMT+0000

Legal Approval	Debra Robinson Legal 10-Dec-2021 12:27:21 GMT+0000

Regulatory Approval	Deanna Koon Regulatory 17-Dec-2021 13:06:07 GMT+0000

Signature Page for MC--00310 v3.0